Open AccessGuidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
Author(s) -
Zhou Jian,
Sun Huichuan,
Wang Zheng,
Cong Wenming,
Wang Jianhua,
Zeng Mengsu,
Zhou Weiping,
Bie Ping,
Liu Lianxin,
Wen Tianfu,
Han Guohong,
Wang Maoqiang,
Liu Ruibao,
Lu Ligong,
Ren Zhengang,
Chen Minshan,
Zeng Zhaochong,
Liang Ping,
Liang Changhong,
Chen Min,
Yan Fuhua,
Wang Wenping,
Ji Yuan,
Yun Jingping,
Cai Dingfang,
Chen Yongjun,
Cheng Wenwu,
Cheng Shuqun,
Dai Chaoliu,
Guo Wenzhi,
Hua Baojin,
Huang Xiaowu,
Jia Weidong,
Li Yaming,
Li Yexiong,
Liang Jun,
Liu Tianshu,
Lv Guoyue,
Mao Yilei,
Peng Tao,
Ren Weixin,
Shi Hongcheng,
Shi Guoming,
Tao Kaishan,
Wang Wentao,
Wang Xiaoying,
Wang Zhiming,
Xiang Bangde,
Xing Baocai,
Xu Jianming,
Yang Jiamei,
Yang Jianyong,
Yang Yefa,
Yang Yunke,
Ye Shenglong,
Yin Zhengyu,
Zhang Bixiang,
Zhang Boheng,
Zhang Leida,
Zhang Shuijun,
Zhang Ti,
Zhao Yongfu,
Zheng Honggang,
Zhu Jiye,
Zhu Kangshun,
Liu Rong,
Shi Yinghong,
Xiao Yongsheng,
Dai Zhi,
Teng Gaojun,
Cai Jianqiang,
Wang Weilin,
Cai Xiujun,
Li Qiang,
Shen Feng,
Qin Shukui,
Dong Jiahong,
Fan Jia
Publication year - 2020
Publication title -
liver cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.916
H-Index - 34
eISSN - 1664-5553
pISSN - 2235-1795
DOI - 10.1159/000509424
Subject(s) - consensus guidelines
Background: Primary liver cancer, around 90% are hepatocellular carcinoma in China, is the fourth most common malignancy and the second leading cause of tumor-related death, thereby posing a significant threat to the life and health of the Chinese people. Summary: Since the publication of Guidelines for Diagnosis and Treatment of Primary Liver Cancer (2017 Edition) in 2018, additional high-quality evidence has emerged with relevance to the diagnosis, staging, and treatment of liver cancer in and outside China that requires the guidelines to be updated. The new edition (2019 Edition) was written by more than 70 experts in the field of liver cancer in China. They reflect the real-world situation in China regarding diagnosing and treating liver cancer in recent years. Key Messages: Most importantly, the new guidelines were endorsed and promulgated by the Bureau of Medical Administration of the National Health Commission of the People’s Republic of China in December 2019.